Nuvation Bio secures $250m for taletrectinib commercialisation [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
The financial move will support Nuvation Bio's present clinical-stage pipeline development. It offers potential profitability without requiring additional capital raising. The financing agreement includes a $150m royalty interest financing and an up-to-$100m senior term loan. Sagard will offer an upfront payment of $150m in cash to Nuvation Bio contingent on US Food and Drug Administration (FDA) approval of the therapy by September 2025. In exchange, Sagard will obtain tiered royalties on the therapy's US net sales. The company will earn 5.5% of annual net sales up to $600m and 3% on sales between $600m and $1bn. Nuvation Bio will retain complete yearly US net sales exceeding $1bn. Royalty payments to Sagard will stop once they reach between 1.6 and 2 times the initial investment, depending on the date. Sagard has also committed to an up-to-$100m five-year, senior secured term loan. The first tranche of $50m will be available upon FDA approval of the therapy, and the second
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Has Nuvation Bio's 234% Surge in 2025 Already Reflected Its Growth Potential? [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NUVB): Reassessing Valuation After a 78% Monthly Surge in the Share Price [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NYSE:NUVB) had its price target raised by analysts at HC Wainwright from $10.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug ListPR Newswire
- Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result [Yahoo! Finance]Yahoo! Finance
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/26/25 - Form 4
- NUVB's page on the SEC website